Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex
Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex.
Beren Therapeutics
Private
Beren Therapeutics is a private late-stage rare-disease biotechnology company developing precision therapies for ultra-rare genetic disorders, with a lead program approaching an FDA filing. The company leverages patient-specific genetic insights to develop targeted small-molecule and antisense therapies.
Company Info
Sector:Biotechnology / Rare Disease
Headquarters:Boston, Massachusetts, USA
Founded:2021
Website:www.berentx.com/
Funding Round:Series C June 2026 ($300M) on path to FDA filing
Total Funding:$500M+ (cumulative)
Funding & Investor Relations
Notable Investors
- Atlas Venture
- OrbiMed
- RA Capital Management
- Bain Capital Life Sciences
- Perceptive Advisors
- Surveyor Capital
IPO Outlook / Plans
Pre-IPO; considering public offering following FDA decision in 2027.
Upcoming Milestones & Key Dates
Late 2026
Regulatory
FDA NDA submission for BER-101 lead rare disease program
H1 2027
Regulatory
Anticipated FDA decision (PDUFA) on BER-101
Clinical Development Pipeline
BER-101
Target: Disease-modifying small moleculeBER-201
Target: Antisense oligonucleotide targeting toxic transcriptBER-301
Target: Liver-targeted ASORecent News
Beren pockets $300m to take Niemann-Pick disease therapy to market
Beren pockets $300m to take Niemann-Pick disease therapy to market.